Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 10/20 | 0.63 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219061 | 0.94 | KDM4E (0.69) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL219356 | 0.90 | CNR1 (0.67) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL2627954 | 0.87 | CNR1 (0.68) | CNR1GABRA2GABRB2CNR2 | |
| SCHEMBL30961554 | 0.87 | CNR1 (0.68) | CNR1GABRA2GABRB2CNR2 | |
| SCHEMBL2874753 | 0.85 | CNR1 (0.66) | CNR1GABRA2GABRB2CNR2 | |
| SCHEMBL3827684 | 0.85 | CNR1 (0.70) | CNR1CNR2 | |
| SCHEMBL4000643 | 0.85 | GABRA2 (0.58) | CNR1GABRA2GABRB2CNR2 | |
| SCHEMBL12053889 | 0.85 | CNR1 (0.62) | CNR1GABRA2GABRB2CNR2 | |
| SCHEMBL4791922 | 0.84 | KDM4E (0.57) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL6766067 | 0.84 | MAPT (0.74) | KDM4EMEN1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632852-B2 | (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7521471-B2 | 4-cyanopyrazole-3-carboxamide derivatives, preparation and application thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20070293541-A1 | 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2007-12-20 | — | — | US | disclosed |
| US-7282516-B2 | 4-cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof | SANOFI-AVENTIS (FR) | 2007-10-16 | — | — | US | disclosed |
| US-20060135776-A1 | 4-Cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof | SANOFI-AVENTIS (FR) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135776-A1 | 4-Cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof | CBR3, CNR1, CNR2 | KDM4E 1523/4885MEN1 2265/4885MAPT 4269/4885 |
| US-20080039510-A1 | (1,5-DIPHENYL-1H-PYRAZOL-3-YL)OXADIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | DHFR, DPYD, THPO | KDM4E 1047/4885MEN1 642/4885MAPT 2328/4885 |
| US-20070293541-A1 | 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF | CBR3, CNR1, CNR2 | KDM4E 1320/4885MEN1 2170/4885MAPT 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.